Thin Wall Cannula

A syringe comprising:

• a reservoir filled with X mL of a 150 mg/mL omalizumab formulation, wherein X is 2, 1 or 0.5, wherein the X mL of the 150 mg/mL omalizumab formulation has 6000 or fewer particles of diameter >10 μm and/or 600 or fewer particles of diameter >25 μm;
• and
• the syringe further comprising:
• a stopper, and
• a needle having a length of 12.7 mm, a gauge of 27, a minimum internal diameter of 0.277 mm, and 5 bevels on its distal surface, the syringe being configured to expel the X mL of the omalizumab formulation contained in the reservoir through the needle when a force is applied to the stopper, wherein one of the following options is fulfilled when a constant force of 10 N is applied to the stopper:
• a) when X is 2, the syringe is configured to expel the omalizumab formulation contained in the reservoir through the needle in less than 16 seconds;
• b) when X is 1, the syringe is configured to expel the omalizumab formulation contained in the reservoir through the needle in less than 5 seconds;
• or
• c) when X is 0.5, the syringe is configured to expel the omalizumab formulation contained in the reservoir through the needle in less than 4 seconds.

A method of treating a patient with of one or more of:

• allergic asthma;
• food allergy;
• chronic rhinosinusitis with nasal polyps;
• chronic spontaneous urticaria;
• nasal polyps;
• moderate to severe persistent asthma in patients with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms that are inadequately controlled with inhaled corticosteroids, the method comprising administering X mL of 150 mg/ml omalizumab formulation to the patient, wherein X is 2, and wherein the X mL 150 mg/mL omalizumab formulation is administered subcutaneously by a syringe, the syringe comprising:
• a reservoir filled with X mL of 150 mg/mL omalizumab formulation, wherein the X mL 150 mg/mL omalizumab formulation has 6000 or fewer particles of diameter>10 μm and/or 600 or fewer particles of diameter>25 μm;
• and the syringe further comprising:
• a stopper, and
• a needle having a gauge of gauge 25 to gauge 29;
• and
• the syringe being configured to expel the omalizumab formulation contained in the reservoir through the needle when a force is applied to the stopper, wherein when a constant force of 10 N is applied to the stopper,
• the syringe is configured to expel the omalizumab formulation contained in the reservoir through the needle in less than 16 seconds.

A syringe comprising:

• a reservoir filled with X mL of 150 mg/mL omalizumab formulation, wherein X is 2, wherein the X mL of 150 mg/mL omalizumab formulation has 6000 or fewer particles of diameter>10 μm and/or 600 or fewer particles of diameter>25 μm;
• and the syringe further comprising:
• a stopper, and
• a needle having a gauge of gauge 25 to gauge 29,
• the syringe being configured to expel X mL of the omalizumab formulation contained in the reservoir through the needle when a force is applied to the stopper, wherein when a constant force of 10 N is applied to the stopper:
• the syringe is configured to expel the omalizumab formulation contained in the reservoir through the needle in less than 16 seconds.

A method of treating a patient with one or more of:

• allergic asthma;
• food allergy;
• chronic rhinosinusitis with nasal polyps;
• chronic spontaneous urticaria;
• nasal polyps;
• moderate to severe persistent asthma in patients with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms that are inadequately controlled with inhaled corticosteroids, the method comprising administering 300 mg omalizumab formulation to the patient, wherein the method comprises administering 2 mL of 150 mg/mL omalizumab formulation subcutaneously by one syringe filled with 2 mL 150 mg/mL omalizumab formulation.